Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- HRP-2 RBP-4 QPlex micro-nutrient
- Product Overview:
The Q-Plex™ Human Micronutrient v2 (7-Plex) is a quantitative chemiluminescent assay (ELISA) allowing concurrent measurement in serum or heparin plasma samples of ?-1-acid glycoprotein (AGP), C-reactive protein (CRP), ferritin, histidine-rich protein II (HRP2), retinol binding protein 4 (RBP4), soluble transferrin receptor (sTfR), and thyroglobulin biomarkers (Tg). The Q-Plex™ Human Micronutrient v2 (7-Plex), developed in partnership with PATH, facilitates micronutrient status surveillance by simplifying laboratory testing and reducing cost. Performance of the Q-Plex™ Human Micronutrient v2 (7-Plex) was optimized to improve precision and recalibrated using samples provided by the Centers for Disease Control Performance Verification Program for Serum Micronutrients as well as the Vital-EQA program. Continued participation in the Vital-EQA program increases confidence in the assay through the elimination of bias. The Q-Plex™ Human Micronutrient v2 (7-Plex) is an accurate and affordable tool for measuring micronutrient biomarkers in serum and plasma samples collected as part of related public health surveillance programs. With the ease of use of a traditional ELISA protocol, the platform will help facilitate testing within the survey country. Q-Plex™ chemiluminescent assays require analysis via the Q-View™ imaging system. See Item No. 28264 for the Q-View™ Imager LS. Species: Human Sample Type: Serum and Heparin Plasma Volume Required per Well: 5 µl, minimum Assay Length: 3.5 hours Intra-Assay Cross-Reactivity: No significant interference ( Assay Type: Competitive and Sandwich ELISA Detection Method: Q-View™ Chemiluminescent Imaging System Item No. 28264 Multiplex Format: 96-well solid plate [Quansys Catalog No. 355149HU]
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.